EP1196165A2 - Azetidine compounds in cns and eye diseases - Google Patents
Azetidine compounds in cns and eye diseasesInfo
- Publication number
- EP1196165A2 EP1196165A2 EP00946187A EP00946187A EP1196165A2 EP 1196165 A2 EP1196165 A2 EP 1196165A2 EP 00946187 A EP00946187 A EP 00946187A EP 00946187 A EP00946187 A EP 00946187A EP 1196165 A2 EP1196165 A2 EP 1196165A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- use according
- azetidine
- trifluoromethyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000030533 eye disease Diseases 0.000 title claims abstract description 8
- 150000001539 azetidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 117
- 238000011282 treatment Methods 0.000 claims abstract description 34
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 239000000651 prodrug Substances 0.000 claims abstract description 15
- 229940002612 prodrug Drugs 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 14
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 12
- 230000004112 neuroprotection Effects 0.000 claims abstract description 12
- 125000003118 aryl group Chemical group 0.000 claims abstract description 11
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 11
- 208000001738 Nervous System Trauma Diseases 0.000 claims abstract description 8
- 208000028412 nervous system injury Diseases 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 4
- 239000001257 hydrogen Substances 0.000 claims abstract description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 43
- -1 4-(trifluoromethyl)phenyl Chemical group 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 36
- 229910001868 water Inorganic materials 0.000 claims description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- JRHGEHVPXIJESH-UHFFFAOYSA-N n-(2-hydroxypropyl)-3-[4-(trifluoromethyl)phenyl]azetidine-1-carboxamide Chemical compound C1N(C(=O)NCC(O)C)CC1C1=CC=C(C(F)(F)F)C=C1 JRHGEHVPXIJESH-UHFFFAOYSA-N 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- QLKRYLUAPDTMMK-SECBINFHSA-N 3-(4-fluorophenyl)-n-[(2r)-2-hydroxypropyl]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC[C@H](O)C)CC1C1=CC=C(F)C=C1 QLKRYLUAPDTMMK-SECBINFHSA-N 0.000 claims description 5
- PVXOUGHWLCBJOW-UHFFFAOYSA-N azetidine-1-carboxamide Chemical compound NC(=O)N1CCC1 PVXOUGHWLCBJOW-UHFFFAOYSA-N 0.000 claims description 5
- 150000002170 ethers Chemical class 0.000 claims description 5
- XJGZWCYMWKCJFW-UHFFFAOYSA-N 3-(4-chlorophenyl)-n-prop-2-ynylazetidine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1CN(C(=O)NCC#C)C1 XJGZWCYMWKCJFW-UHFFFAOYSA-N 0.000 claims description 4
- 229920000858 Cyclodextrin Polymers 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 57
- 239000000243 solution Substances 0.000 description 47
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 208000006011 Stroke Diseases 0.000 description 17
- 239000012267 brine Substances 0.000 description 17
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 17
- 208000028867 ischemia Diseases 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- IYGJPNAEMKBWCF-UHFFFAOYSA-N 1-benzhydryl-3-(4-fluorophenyl)azetidine Chemical compound C1=CC(F)=CC=C1C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1 IYGJPNAEMKBWCF-UHFFFAOYSA-N 0.000 description 11
- LKPALSUBQRWDMZ-UHFFFAOYSA-N 1-benzhydryl-3-(4-tert-butylphenyl)azetidine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1 LKPALSUBQRWDMZ-UHFFFAOYSA-N 0.000 description 10
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 10
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000007912 intraperitoneal administration Methods 0.000 description 9
- HYMUREYQKUJWIQ-UHFFFAOYSA-N 1-benzhydryl-3-[4-(trifluoromethyl)phenyl]azetidine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1 HYMUREYQKUJWIQ-UHFFFAOYSA-N 0.000 description 8
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 8
- 206010061216 Infarction Diseases 0.000 description 8
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 8
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 230000007574 infarction Effects 0.000 description 8
- AVUDXLOVIBJFQA-UHFFFAOYSA-N 1-benzhydrylazetidin-3-one Chemical compound C1C(=O)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 AVUDXLOVIBJFQA-UHFFFAOYSA-N 0.000 description 7
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229960004414 clomethiazole Drugs 0.000 description 7
- 238000003818 flash chromatography Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- VDECBPZVCMSIKK-UHFFFAOYSA-N 1-benzhydryl-3-(4-tert-butylphenyl)-3-chloroazetidine Chemical compound C1=CC(C(C)(C)C)=CC=C1C1(Cl)CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1 VDECBPZVCMSIKK-UHFFFAOYSA-N 0.000 description 6
- UPXXQMBUBSHBEZ-UHFFFAOYSA-N 3-(4-chlorophenyl)azetidine Chemical compound C1=CC(Cl)=CC=C1C1CNC1 UPXXQMBUBSHBEZ-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000003657 middle cerebral artery Anatomy 0.000 description 6
- JKANAVGODYYCQF-UHFFFAOYSA-N prop-2-yn-1-amine Chemical compound NCC#C JKANAVGODYYCQF-UHFFFAOYSA-N 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- HXKKHQJGJAFBHI-GSVOUGTGSA-N (2R)-1-aminopropan-2-ol Chemical compound C[C@@H](O)CN HXKKHQJGJAFBHI-GSVOUGTGSA-N 0.000 description 5
- YFUOIHFQICAKTD-UHFFFAOYSA-N 1-benzhydryl-3-(4-chlorophenyl)azetidine Chemical compound C1=CC(Cl)=CC=C1C1CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1 YFUOIHFQICAKTD-UHFFFAOYSA-N 0.000 description 5
- BMELHQNFXXRNIQ-UHFFFAOYSA-N 1-benzhydryl-3-(4-tert-butylphenyl)azetidin-3-ol Chemical compound C1=CC(C(C)(C)C)=CC=C1C1(O)CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1 BMELHQNFXXRNIQ-UHFFFAOYSA-N 0.000 description 5
- IRPMIKJQQYLTLF-UHFFFAOYSA-N 1-benzhydryl-3-chloro-3-(4-fluorophenyl)azetidine Chemical compound C1=CC(F)=CC=C1C1(Cl)CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1 IRPMIKJQQYLTLF-UHFFFAOYSA-N 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 5
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 5
- 230000000324 neuroprotective effect Effects 0.000 description 5
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- HXKKHQJGJAFBHI-VKHMYHEASA-N (2s)-1-aminopropan-2-ol Chemical compound C[C@H](O)CN HXKKHQJGJAFBHI-VKHMYHEASA-N 0.000 description 4
- DMDDOOGJRZVTPH-UHFFFAOYSA-N 1-benzhydryl-3-(4-fluorophenyl)azetidin-3-ol Chemical compound C1C(O)(C=2C=CC(F)=CC=2)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 DMDDOOGJRZVTPH-UHFFFAOYSA-N 0.000 description 4
- MUQSWQVSMWULTQ-UHFFFAOYSA-N 3-(4-chlorophenyl)-n-prop-2-enylazetidine-1-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1CN(C(=O)NCC=C)C1 MUQSWQVSMWULTQ-UHFFFAOYSA-N 0.000 description 4
- HUYMODRJYUULAH-UHFFFAOYSA-N 3-(4-fluorophenyl)-n-prop-2-enylazetidine-1-carboxamide Chemical compound C1=CC(F)=CC=C1C1CN(C(=O)NCC=C)C1 HUYMODRJYUULAH-UHFFFAOYSA-N 0.000 description 4
- QVPWVDDTWHXDRN-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-prop-2-ynylazetidine-1-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C1CN(C(=O)NCC#C)C1 QVPWVDDTWHXDRN-UHFFFAOYSA-N 0.000 description 4
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical compound NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 239000012300 argon atmosphere Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229960003472 felbamate Drugs 0.000 description 4
- WKGXYQFOCVYPAC-UHFFFAOYSA-N felbamate Chemical compound NC(=O)OCC(COC(N)=O)C1=CC=CC=C1 WKGXYQFOCVYPAC-UHFFFAOYSA-N 0.000 description 4
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- YRGZMKRIXHMRNX-UHFFFAOYSA-N 1-benzhydryl-3-(3,4-dichlorophenyl)azetidin-3-ol Chemical compound C1C(O)(C=2C=C(Cl)C(Cl)=CC=2)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 YRGZMKRIXHMRNX-UHFFFAOYSA-N 0.000 description 3
- SRZSUMAQPHBUSC-UHFFFAOYSA-N 1-benzhydryl-3-[4-(trifluoromethyl)phenyl]azetidin-3-ol Chemical compound C1C(O)(C=2C=CC(=CC=2)C(F)(F)F)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 SRZSUMAQPHBUSC-UHFFFAOYSA-N 0.000 description 3
- HEUFZTLXURWUFI-UHFFFAOYSA-N 1-benzhydryl-3-chloro-3-(3,4-dichlorophenyl)azetidine Chemical compound C1=C(Cl)C(Cl)=CC=C1C1(Cl)CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1 HEUFZTLXURWUFI-UHFFFAOYSA-N 0.000 description 3
- MYEBRPUMBHIGRU-UHFFFAOYSA-N 1-benzhydryl-3-chloro-3-[3-(trifluoromethyl)phenyl]azetidine Chemical compound FC(F)(F)C1=CC=CC(C2(Cl)CN(C2)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 MYEBRPUMBHIGRU-UHFFFAOYSA-N 0.000 description 3
- YGKXDDBWBDBTSB-UHFFFAOYSA-N 1-benzhydryl-3-chloro-3-[4-(trifluoromethyl)phenyl]azetidine Chemical compound C1=CC(C(F)(F)F)=CC=C1C1(Cl)CN(C(C=2C=CC=CC=2)C=2C=CC=CC=2)C1 YGKXDDBWBDBTSB-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 208000032382 Ischaemic stroke Diseases 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 229940099983 activase Drugs 0.000 description 3
- 125000002015 acyclic group Chemical group 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 230000001120 cytoprotective effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000002964 excitative effect Effects 0.000 description 3
- 230000003492 excitotoxic effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000003371 gabaergic effect Effects 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229960004526 piracetam Drugs 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- BYRQRZLCDNKLGL-UHFFFAOYSA-N 1-benzhydryl-3-[3-(trifluoromethyl)phenyl]azetidin-3-ol Chemical compound C1C(O)(C=2C=C(C=CC=2)C(F)(F)F)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 BYRQRZLCDNKLGL-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- DPLZYMSATHAINI-MRVPVSSYSA-N 3-(3,4-dichlorophenyl)-n-[(2r)-2-hydroxypropyl]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC[C@H](O)C)CC1C1=CC=C(Cl)C(Cl)=C1 DPLZYMSATHAINI-MRVPVSSYSA-N 0.000 description 2
- DPLZYMSATHAINI-QMMMGPOBSA-N 3-(3,4-dichlorophenyl)-n-[(2s)-2-hydroxypropyl]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC[C@@H](O)C)CC1C1=CC=C(Cl)C(Cl)=C1 DPLZYMSATHAINI-QMMMGPOBSA-N 0.000 description 2
- QLKRYLUAPDTMMK-VIFPVBQESA-N 3-(4-fluorophenyl)-n-[(2s)-2-hydroxypropyl]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC[C@@H](O)C)CC1C1=CC=C(F)C=C1 QLKRYLUAPDTMMK-VIFPVBQESA-N 0.000 description 2
- XOWHSHKUGGFFAO-GFCCVEGCSA-N 3-(4-tert-butylphenyl)-n-[(2r)-2-hydroxypropyl]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC[C@H](O)C)CC1C1=CC=C(C(C)(C)C)C=C1 XOWHSHKUGGFFAO-GFCCVEGCSA-N 0.000 description 2
- HGGBUHIEOFXIOX-UHFFFAOYSA-N 3-(4-tert-butylphenyl)-n-prop-2-enylazetidine-1-carboxamide Chemical compound C1=CC(C(C)(C)C)=CC=C1C1CN(C(=O)NCC=C)C1 HGGBUHIEOFXIOX-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 229910019142 PO4 Chemical group 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000007868 Raney catalyst Substances 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical group 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- QOPVNWQGBQYBBP-UHFFFAOYSA-N chloroethyl chloroformate Chemical compound CC(Cl)OC(Cl)=O QOPVNWQGBQYBBP-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 231100000063 excitotoxicity Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000003445 gaba agent Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000000848 glutamatergic effect Effects 0.000 description 2
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 2
- 229960003132 halothane Drugs 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000030214 innervation Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- IWATWXGYALNBNL-SECBINFHSA-N n-[(2r)-2-hydroxypropyl]-3-[3-(trifluoromethyl)phenyl]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC[C@H](O)C)CC1C1=CC=CC(C(F)(F)F)=C1 IWATWXGYALNBNL-SECBINFHSA-N 0.000 description 2
- JRHGEHVPXIJESH-SECBINFHSA-N n-[(2r)-2-hydroxypropyl]-3-[4-(trifluoromethyl)phenyl]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC[C@H](O)C)CC1C1=CC=C(C(F)(F)F)C=C1 JRHGEHVPXIJESH-SECBINFHSA-N 0.000 description 2
- FYGMYXQRFFXYFI-UHFFFAOYSA-N n-prop-2-ynyl-3-[3-(trifluoromethyl)phenyl]azetidine-1-carboxamide Chemical compound FC(F)(F)C1=CC=CC(C2CN(C2)C(=O)NCC#C)=C1 FYGMYXQRFFXYFI-UHFFFAOYSA-N 0.000 description 2
- UIZDSIWZGBMXHR-UHFFFAOYSA-N n-prop-2-ynyl-3-[4-(trifluoromethyl)phenyl]azetidine-1-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1C1CN(C(=O)NCC#C)C1 UIZDSIWZGBMXHR-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000010452 phosphate Chemical group 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- OVJRXDKPEKRGFB-UHFFFAOYSA-N 1-benzhydryl-3-(4-chlorophenyl)azetidin-3-ol Chemical compound C1C(O)(C=2C=CC(Cl)=CC=2)CN1C(C=1C=CC=CC=1)C1=CC=CC=C1 OVJRXDKPEKRGFB-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- JREUHGFVPKPLOH-UHFFFAOYSA-N 3-(4-fluorophenyl)-n-prop-2-ynylazetidine-1-carboxamide Chemical compound C1=CC(F)=CC=C1C1CN(C(=O)NCC#C)C1 JREUHGFVPKPLOH-UHFFFAOYSA-N 0.000 description 1
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229940122226 Benzodiazepine receptor agonist Drugs 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- CDEMHJCJMMOFMB-UHFFFAOYSA-M ClC1=CC=C([Mg]Br)C=C1 Chemical compound ClC1=CC=C([Mg]Br)C=C1 CDEMHJCJMMOFMB-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 206010014498 Embolic stroke Diseases 0.000 description 1
- 229940091860 GABA uptake inhibitor Drugs 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010018985 Haemorrhage intracranial Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000004552 Lacunar Stroke Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 206010028923 Neonatal asphyxia Diseases 0.000 description 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000037111 Retinal Hemorrhage Diseases 0.000 description 1
- 201000007527 Retinal artery occlusion Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229940127505 Sodium Channel Antagonists Drugs 0.000 description 1
- 208000036982 Spinal cord ischaemia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010043647 Thrombotic Stroke Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- IPMRFNJFZBOIKO-UHFFFAOYSA-M [Br-].FC(F)(F)C1=CC=C([Mg+])C=C1 Chemical compound [Br-].FC(F)(F)C1=CC=C([Mg+])C=C1 IPMRFNJFZBOIKO-UHFFFAOYSA-M 0.000 description 1
- WSWOKFODOPIESP-UHFFFAOYSA-M [Br-].FC(F)(F)C1=CC=CC([Mg+])=C1 Chemical compound [Br-].FC(F)(F)C1=CC=CC([Mg+])=C1 WSWOKFODOPIESP-UHFFFAOYSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005197 alkyl carbonyloxy alkyl group Chemical group 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004688 alkyl sulfonyl alkyl group Chemical group 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- HXBPYFMVGFDZFT-UHFFFAOYSA-N allyl isocyanate Chemical compound C=CCN=C=O HXBPYFMVGFDZFT-UHFFFAOYSA-N 0.000 description 1
- 229960003318 alteplase Drugs 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002424 anti-apoptotic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 125000005099 aryl alkyl carbonyl group Chemical group 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000005100 aryl amino carbonyl group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 150000004792 aryl magnesium halides Chemical class 0.000 description 1
- 125000005160 aryl oxy alkyl group Chemical group 0.000 description 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 239000000759 benzodiazepine receptor stimulating agent Substances 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 108010079785 calpain inhibitors Proteins 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 125000000332 coumarinyl group Chemical group O1C(=O)C(=CC2=CC=CC=C12)* 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000004966 cyanoalkyl group Chemical group 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 238000009297 electrocoagulation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- LJWKFGGDMBPPAZ-UHFFFAOYSA-N ethoxyethane;toluene Chemical compound CCOCC.CC1=CC=CC=C1 LJWKFGGDMBPPAZ-UHFFFAOYSA-N 0.000 description 1
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000002843 gaba uptake inhibitor Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000011556 gerbil model Methods 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Chemical group OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 208000001286 intracranial vasospasm Diseases 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000003151 isocoumarinyl group Chemical group C1(=O)OC(=CC2=CC=CC=C12)* 0.000 description 1
- 125000005438 isoindazolyl group Chemical group 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000008263 liquid aerosol Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- RMXGWLUCCKWPGK-UHFFFAOYSA-M magnesium;1,2-dichlorobenzene-5-ide;bromide Chemical compound [Mg+2].[Br-].ClC1=CC=[C-]C=C1Cl RMXGWLUCCKWPGK-UHFFFAOYSA-M 0.000 description 1
- BRKADVNLTRCLOW-UHFFFAOYSA-M magnesium;fluorobenzene;bromide Chemical compound [Mg+2].[Br-].FC1=CC=[C-]C=C1 BRKADVNLTRCLOW-UHFFFAOYSA-M 0.000 description 1
- JFWSITPEDQPZNZ-UHFFFAOYSA-M magnesium;tert-butylbenzene;bromide Chemical compound [Mg+2].[Br-].CC(C)(C)C1=CC=[C-]C=C1 JFWSITPEDQPZNZ-UHFFFAOYSA-M 0.000 description 1
- 238000013291 male lister hooded rat Methods 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- JRHGEHVPXIJESH-VIFPVBQESA-N n-[(2s)-2-hydroxypropyl]-3-[4-(trifluoromethyl)phenyl]azetidine-1-carboxamide Chemical compound C1N(C(=O)NC[C@@H](O)C)CC1C1=CC=C(C(F)(F)F)C=C1 JRHGEHVPXIJESH-VIFPVBQESA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000007512 neuronal protection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 238000011859 neuroprotective therapy Methods 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000033300 perinatal asphyxia Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004590 pyridopyridyl group Chemical group N1=C(C=CC2=C1C=CC=N2)* 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006042 reductive dechlorination reaction Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical group [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003568 thioethers Chemical group 0.000 description 1
- 150000003573 thiols Chemical group 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 1
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012991 xanthate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates primarily to neuroprotection and to the treatment of stroke and other cerebrovascular disorders.
- Stroke and other acute brain injuries are major causes of mortality and morbidity in the adult population. Stroke is the third highest cause of death in major industrialised countries and the commonest cause of permanent disability. Each year, in the US and Europe, approximately 1 million people suffer an acute stroke. Between 25% and 35% of these patients die within the first three weeks, and of the survivors 25% to 50% will be totally dependant on family or institutional care for the rest of their lives. The incidence of stroke increases with age, roughly doubling with each passing decade, with 30% of persons aged over 65 years being affected.
- Activase ® Genetech's thrombolytic recombinant tissue plasminogen activator
- Activase is indicated for the management of acute ischaemic stroke in adults for improving neurological recovery and reducing the incidence of disability.
- Treatment with Activase should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial haemorrhage by a cranial computerised tomography (CT) scan or other diagnostic imaging method sensitive for the presence of haemorrhage.
- CT computerised tomography
- Cytoprotective neuroprotective therapy includes drugs that act to prevent cell death during ischaemia and reperfusion.
- agents include calpain inhibitors, voltage-sensitive calcium- and sodium-channel antagonists, receptor-mediated calcium-channel antagonists [including N-methyl-D-aspartate (NMDA) and ⁇ -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMP A) antagonists], glutamate-synthesis inhibitors, glutamate-release antagonists, ⁇ -aminobenzoic acid (GABA) antagonists, 5-HT (serotonin) receptor agonists, gangliosides, antioxidants, growth factors, antiapoptotic agents, and antiadhesion molecules (Silver, B., Weber, J., Fisher, M., Clin. Neuropharmacol. 1996, 19, 101-128).
- NMDA N-methyl-D-aspartate
- AMP A ⁇ -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
- glutamate-synthesis inhibitors glutamate-release antagonists
- GABA ⁇ -aminobenzoic
- Excitotoxicity is a major determinant of neuronal death following the induction of cerebral ischaemia. Repetitive cell firing, persistent depolarisation and induction of supra-normal ionic flux across excitable membranes can initiate fatal cellular compromise via a variety of synergistic mechanisms during hypoxic excitotoxicity. Control of the state of excitability of neurons depends upon the net balance of excitatory and inhibitory influences acting on that neurone.
- the primary excitatory influence impinging on neurones is mediated by the glutamatergic system, whilst primary inhibition is frequently determined by GABAergic innervation, since the main endogenous inhibitory amino acid in mammalian brain is GABA.
- GABAergic innervation the main endogenous inhibitory amino acid in mammalian brain is GABA.
- GABA uptake inhibitors such as CI-966, which was shown to be effective in a gerbil ischaemia model utilising global cerebral ischaemia of 5 min. duration (Phillis, J.W., Gen. Pharmacol. 1995, 26, 1061-1064).
- the benzodiazepine receptor agonist diazepam has been shown to possess some neuroprotective properties (Karle, J., Witt, M. R., Nielsen, M., Brain Res. 1997, 765, 21- 29).
- Felbamate an antiepileptic drug with inter alia GABA agonist properties, provided significant neuronal protection when administered both before and after ischaemia in all regions of the brain in the gerbil model of transient forebrain ischaemia. Protection was moderate when felbamate was used before ischaemia, but was highly significant when felbamate was given 30 min. after the insult. The structural protection with felbamate was very significant when used in the post-ischaemic period (Shuaib, A., Waqaar, T., Ijaz, M.S., Kanthan, R., Wishart, T., Howlett, W., Brain Res. 1996, 727, 65-70).
- Piracetam is a derivative of GABA, and was the first commercially available nootropic drug. Although widely evaluated in the treatment of senile cognitive disorders and dyslexia, piracetam has also been assessed as a treatment for deficits associated with acute stroke. Data from a number of small, short term studies in patients treated within a few days of stroke suggest that piracetam is more effective than placebo for the treatment of functional deficits (Noble, S., Benfield, P., CNS Drugs 1998, 9, 497-511).
- WO-A-99/25353 discloses the use of triazolo[4,3-b]pyridazine derivatives as benzodiazepine/GABAA modulators for the treatment of psychotic disorders and neurodegeneration.
- WO-A-90/09174 discloses the use of the GABAergic agent Clomethiazole (chlormethiazole) in the prevention and/or treatment of neurodegeneration. Clomethiazole is thought to act through a GABAergic pathway, whereby it augments GABA's inhibitory effect on the CNS, giving the drug both hypnotic and neuroprotectant properties.
- Azetidine-1-carboxamides and the use of these compounds in the treatment of anxiety and all forms of epilepsy is described in International Patent Application No. PCT/GB99/00223.
- the object of the present invention is to provide such treatments.
- azetidine-1-carboxamides show unexpected neuroprotectant efficacy when compared to reference GABAergic agents.
- certain azetidine-1-carboxamides have been shown to potentiate the action of GABA in inhibiting neurones, and have also been shown to prevent the repetitive firing induced as a consequence of activation of glutamatergic mechanisms.
- Such compounds are found to be neuroprotective following acute cerebral ischaemia in rats and mice, and reduced ischaemia-induced CNS damage in in vivo models of focal ischaemia in both species. According to the present invention, there is provided the use of a compound of formula (I)
- R 1 is aryl; and R 2 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for neuroprotection in a subject or for the treatment of cerebral ischaemia, central nervous system injury or eye diseases.
- alkyl means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical.
- the alkyl group is preferably Ci to Cj 2 , more preferably d to C 8 (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, hexyl, heptyl, octyl).
- alkyl as used herein includes alkyl (branched or unbranched), alkenyl (branched or unbranched), alkynyl (branched or unbranched), cycloalkyl, cycloalkenyl and cycloalkynyl.
- a cyclic alkyl group is preferably C 3 to 2 , more preferably C 5 to and an acyclic alkyl group is preferably Ci to do, more preferably Ci to C 6 , more preferably methyl, ethyl, propyl (n- propyl or isopropyl), butyl (n-butyl, isobutyl or tertiary-butyl) or pentyl (including n-pentyl and iso-pentyl), more preferably methyl.
- aryl means a mono or bicyclic aromatic group, such as phenyl or naphthyl.
- the alkyl and aryl groups may be substituted or unsubstituted. In one embodiment, only the aryl group defined above as Rj and the alkyl group defined above as R 2 may be substituted. Where substituted, there will generally be 1 to 3 substituents present, preferably 1 or 2 substituents.
- Substituents may include: carbon containing groups such as alkyl aryl, arylalkyl (e.g. substituted and unsubstituted phenyl, substituted and unsubstituted benzyl); halogen atoms and halogen containing groups such as haloalkyl (e.g. trifluoromethyl); oxygen containing groups such as alcohols (e.g.
- ethers e.g. alkoxy, alkoxyalkyl, aryloxyalkyl
- aldehydes e.g. carboxaldehyde
- ketones e.g. alkylcarbonyl, alkylcarbonylalkyl, arylcarbonyl, arylalkylcarbonyl, arylcarbonylalkyl
- acids e.g. carboxy, carboxyalkyl
- acid derivatives such as esters (e.g. alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl) and amides
- aminocarbonyl e.g. aminocarbonyl, mono- or dialkylaminocarbonyl, aminocarbonylalkyl, mono- or dialkylaminocarbonylalkyl, arylaminocarbonyl
- nitrogen containing groups such as amines (e.g. amino, mono- or dialkylamino, aminoalkyl, mono- or dialkylaminoalkyl), azides, nitriles (e.g. cyano, cyanoalkyl), nitro; sulphur containing groups such as thiols, thioethers, sulphoxides and sulphones
- alkylthio alkylsulfinyl, alkylsufonyl, alkylthioalkyl, alkylsulfmylalkyl, alkylsulfonylalkyl, arylthio, arylsulfinyl, arylsulfonyl, arylthioalkyl, arylsulfinylalkyl, arylsulfonylalkyl); and
- Preferred substituents include alkyl, aryl, halo, or an halogen-containing group such as trifluoromethyl.
- alkoxy means alkyl-O- and "alkoyl” means alkyl-CO-.
- halogen means a fluorine, chlorine, bromine or iodine radical, preferably a fluorine or chlorine radical.
- the compounds of formula (I) may exist in a number of diastereomeric and/or enantiomeric forms. Unless otherwise stated, reference in the present specification to "a compound of formula (I)" is a reference to all stereoisomeric forms of the compound and includes a reference to the unseparated stereoisomers in a mixture, racemic or non-racemic, and to each stereoisomer in its pure form.
- a compound of formula (I) is the (R - enantiomer of the compound of formula (I), substantially free of its (S)-enantiomer.
- R 1 is a substituted or unsubstituted aryl group selected from phenyl and naphthyl, more preferably R 1 is a substituted phenyl or naphthyl, more preferably R 1 is phenyl or naphthyl having 1 to 3 substituents and most preferably R 1 is phenyl or naphthyl having 1 or 2 substituents.
- R 1 is a mono- or di-substituted phenyl group, preferably a mono-substituted phenyl group.
- R 1 is napthyl, it is preferred that R 1 is 2-naphthyl.
- the preferred substituent groups are selected from halo (preferably fluoro and chloro), trifluoromethyl and tertiary butyl, and more preferably from fluoro, chloro and trifluoromethyl.
- R 1 is a phenyl having 1 substituent
- the phenyl group is preferably para- or meta-substituted.
- the phenyl group is preferably 2,3-disubstituted, 2,4-disubstituted, 3,4-disubstituted or 3,5-disubstituted, preferably 3,4- disubstituted.
- R 1 is disubstituted, it is preferred that R 1 is substituted by two halo groups, the same or different, or by one halo group and one trifluoromethyl group. More preferably, R 1 is dichloro-, difluoro-, chloro-fluoro- or fluoro-trifluoromethyl-substituted.
- the R 1 groups are preferably selected from 4-chlorophenyl, 4-fluorophenyl, 4- (trifluoromethyl)phenyl, 3-(trifluoromethyl)phenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluorophenyl, 4-chloro-3-fluorophenyl, 3-fluoro-4-(trifluoromethyl)phenyl, 4- fluoro-3-(trifluoromethyl)phenyl and 3-chloro-5-fluorophenyl.
- R is alkyl, preferably selected from C ⁇ -8 alkyl, more preferably from alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl and unsubstituted saturated cyclic and acyclic hydrocarbyl, and more preferably from propyl, 2-propenyl, 2-propynyl and 2-hydroxypropyl.
- Particularly preferred compounds are as follows:-
- the compound of formula (I) is 3-(4- (trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine-l-carboxamide (la) or a pharmaceutically acceptable salt or prodrug thereof.
- the compound of formula (I) is the (r?)-enantiomer of 3 -(4-(trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine- 1 -carboxamide (lb), substantially free of its (S)-enantiomer, or a pharmaceutically acceptable salt or prodrug thereof.
- a method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of the compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
- a method of treatment of cerebral ischaemia, central nervous system injury or eye diseases comprising administration to a subject in need of such treatment an effective dose of the compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
- the present invention may be employed in respect of a human or animal subject, more preferably a mammal, more preferably a human subject.
- treatment includes prophylactic treatment.
- prodrug means any pharmaceutically acceptable prodrug of the compound of formula (I).
- the compound of formula (I) may be prepared in a prodrug form wherein a free -OH group is derivatised (for example, via an ester, amide or phosphate bond) with a suitable group (the group may contain, for example, an alkyl, aryl, phosphate, sugar, amine, glycol, sulfonate or acid function) which is suitably labile so as it will be removed / cleaved (eg. by hydrolysis) to reveal the compound of formula (I) sometime after administration or when exposed to the desired biological environment.
- salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, furnaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like.
- acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, furnaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic,
- hydrochloric, hydrobromic, phosphoric, sulfuric and methanesulfonic acids particularly preferred are hydrochloric, hydrobromic, phosphoric, sulfuric and methanesulfonic acids, and most particularly preferred is the methanesulfonate salt.
- Acceptable base salts include alkali metal (e.g. sodium, potassium), alkaline earth metal (e.g. calcium, magnesium) and aluminium salts.
- the term "substantially free of its (S)-enantiomer” means that the medicament or therapeutic composition comprising the compound of formula (I) used according to the present invention contains a greater proportion of the (R)-enantiomer of the compound of formula (I) in relation to the (S)-enantiomer of the compound of formula (I).
- the term "substantially free of its (S)-enantiomer”, as used herein, means that the composition contains at least 90 % by weight of the (i?)-enantiomer and 10 % by weight or less of the (S)-enantiomer.
- the term "substantially free of its (S)-enantiomer” means that the composition contains at least 99 % by weight of the K)-enantiomer and 1 % or less of the (S)-enantiomer. In another preferred embodiment, the term “substantially free of its (S)-enantiomer” means that the composition contains 100 % by weight of the (R)- enantiomer. The above percentages are based on the total amount of compound of formula (I) present in the medicament or therapeutic composition used according to the present invention.
- Cerebral Ischaemia including transient ischaemic attack, stroke (thrombotic stroke, ischaemic stroke, embolic stroke, haemorrhagic stroke, lacunar stroke), subarachnoid haemorrhage, cerebral vasospasm, neuroprotection for stroke, peri-natal asphyxia, drowning, carbon monoxide poisoning, cardiac arrest and subdural haematoma; Central Nervous System Injury, including traumatic brain injury, neurosurgery (surgical trauma), neuroprotection for head injury, raised intracranial pressure, cerebral oedema, hydrocephalus and spinal cord injury; and Eye Diseases, including drug-induced optic neuritis, cataract, diabetic neuropathy, ischaemic retinopathy, retinal haemorrhage, retinitis pigmentosa, acute glaucoma, chronic glaucoma, macular degeneration, retinal artery occlusion and
- the compound of formula (I) may also be used to potentiate the effects of other treatments, for example to potentiate the neuroprotective effects of brain derived nerve growth factor.
- the invention is particularly directed to the treatment of cerebral ischaemia and central nervous system injury.
- the invention is also particularly directed to the treatment of post- asphyxial brain damage in new-born subjects.
- the compound of formula (I) may be used in combination with one or more additional drugs useful in the treatment of the disorders mentioned above, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.
- the 3-aryl-3-azetidinol (LU) may be formed by treatment of the ketone (II) with an organometallic reagent such as an aryllithium or an arylmagnesium halide.
- Removal of the hydroxyl group to give the 3- arylazetidine (TV) may be effected by several methods including, for example, catalytic hydrogenolysis; treatment with lithium or sodium and ammonia; conversion to the xanthate by treatment with carbon disulphide, methyl iodide and base, followed by tin-mediated reduction; and conversion to the 3-aryl-3-chloroazetidine analogue using an alkylsulfonyl chloride and a base, followed by a reductive dechlorination using sodium, lithium or nickel. Formation of the azetidine (V) is achieved by reaction of (IV) with a suitable nitrogen deprotection agent.
- deprotection may be carried out by either catalytic transfer hydrogenation (e.g. ammonium formate and palladium catalyst) or by treatment with 1-chloroethyl chloroformate followed by methanol.
- the urea (I) is formed by reaction of azetidine (V) with an N-alkylisocyanate or an N-alkylcarbamoyl chloride and a base such as triethylamine or potassium carbonate.
- the urea may be prepared directly from the azetidine (TV) without isolation of an intermediate such as the secondary amine (V).
- azetidine (IV) may be treated with phosgene followed by amme R NH to give urea (I) directly.
- the invention further provides a pharmaceutical composition comprising an effective amount of the compound of formula (I) in combination with a pharmaceutically acceptable carrier or excipient and a method of making such a composition comprising combining an effective amount of the compound of formula (I) with a pharmaceutically acceptable carrier or excipient.
- the composition may contain components such as dextrans or cyclodextrins or ether derivatives thereof, which aid stability and dispersion, and decrease metabolism of the active ingredient.
- compositions in which the pharmaceutically acceptable carrier comprises a cyclodextrin or an ether derivative thereof the active ingredient is intimately mixed with an aqueous solution of the cyclodextrin or ether derivative thereof, with optional addition of further pharmaceutically acceptable ingredients before, during or after said mixing.
- the thus obtained solution is optionally lyophilized, and the lyophilized residue is optionally reconstituted with water.
- the composition further comprises a buffer system, an isotonizing agent and water.
- Compounds of formula (I) may be administered in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use including transmucosal and transdermal use, for example a cream, ointment, gel, aqueous or oil solution or suspension, salve, patch or plaster; for nasal use, for a example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for administration by inhalation, for example a finely divided powder or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oil solution cr suspension.
- the above compositions may be prepared in a conventional manner using conventional excipients, using standard techniques well known to those skilled in the art of pharmacy.
- the compound is administered
- the compounds of formula (I) will generally be provided in the form of tablets or capsules or as an aqueous solution or suspension.
- Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives.
- suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents.
- Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc.
- the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
- Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.
- the compounds of formula (I) will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity.
- Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
- Aqueous suspensions may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin.
- Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.
- dosage levels used may vary over quite a wide range depending upon the compound used, the severity of the symptoms exhibited by the patient and the patient's body weight.
- the compound (2) was prepared according to the method of Anderson and Lok (J Org. Chem. 1972, 37, 3953, the disclosure of which is incorporated herein by reference), m.p. 111- 112 °C (lit. m.p. 113 °C).
- This compound was prepared from 3-(4-chlorophenyl-l-(diphenylmethyl)azetidine (6) and propargylamine using the procedure outlined in Example 3, m.p. 160 °C (diethyl ether). Found C, 62.85; H, 5.38; N, 10.89 C 13 H 13 ClN 2 O requires C, 62.78; H, 5.27; N, 11.26%.
- This compound was prepared from compound (3) and 3,4-dichlorophenylmagnesium bromide using the procedure described for compound (4).
- This compound was prepared from compound (26) and propargylamine using the procedure described for compound (12). m.p. 105.5-107.5°C.
- This compound was prepared from compound (3) and 4-(trifluoromethyl)phenylmagnesium bromide using the procedure described for compound (4).
- This compound was prepared from compound (30) using the procedure described for compound (10).
- This product was prepared from compound (32) and propargylamine using the procedure described for compound (12). m.p. 151-155°C.
- This compound was prepared from compound (3) and 3-(trifluoromethyl)phenylmagnesium bromide using the procedure described for compound (4).
- This compound was prepared from compound (32) using the procedure described for compound (10).
- This compound was prepared from compound (38) and (R)-l-amino-2-propanol using the procedure described for compound (12). m.p. 81-82°C.
- This compound was prepared from compound (38) and (S)-l-amino-2-propanol using the procedure described for compound (12). m.p. 80-82°C.
- This product was prepared from compound (38) and propargylamine using the procedure described for compound (12). m.p. 121°C.
- Footnote a IR: 3373, 3316, 2923, 2855, 1639, 1620, 1557, 1488, 1462, 1434, 1378, 1304, 1153, 815 cm “1 .
- Footnote b IR: 3500, 3429, 3346, 3274, 2925, 2854, 1614, 1556, 1466, 1420, 1407, 1052, 824, 536 cm "1 .
- Footnote c IR: 3414, 3320, 3253, 2925, 2855, 1606, 1544, 1492, 1460, 1376, 1316, 1092,
- Footnote d IR: 3340, 3166, 2923, 2854, 1650, 1613, 1493, 1460, 1378, 1303, 1098, 820 cm "1 .
- Footnote e IR: 3310, 2964, 2878, 1632, 1538, 1494, 1482, 1462, 1398, 1328, 1093, 1015,
- Footnote f compound (102) was made by the oxidation of compound (33), by methods known to those skilled in the art.
- Footnote g: compound (104) was made from compound (102) by methods known to those skilled in the art.
- This model of middle cerebral artery occlusion used relies on an intraluminal filament technique in the rat (Zhao Q. et al, Acta Physiol. Scand. 1994, 152, 349-350).
- Male Lister Hooded rats were used in these experiments and were divided into three groups (Group 1 : vehicle; Group 2: chlomethiazole (CMZ); Group 3: a compound of formula I). The sample size in each was 11 to 15. The animal was anaesthetised and the carotid artery exposed.
- a heat rounded dermalon suture (3/0) of a specified diameter was introduced into the ligated carotid artery, past the bifurcations of the external and common carotid, the internal carotid and the pterygopalatine artery, into the intracranial circulation.
- the filament then lodged in the narrow proximal anterior carotid occluding the middle cerebral artery. After 90 min. of middle cerebral artery occlusion, the filament was removed, allowing re-circulation. 22.5 h following reperfusion, the animal was perfused via the transaortic route, using 200 ml of a 4 percent solution of tetrazolium chloride warmed to 37° C.
- the brain was removed and immersion fixed in 10 percent formalin/saline for at least 48 h. Following fixation, the brain was sliced into 0.5 mm sections on a vibroslice. Using this technique, viable tissue was stained dark red and infarcted tissue remains unstained. The area of infarction on each section was measured, and the total volume of infarction in the hemisphere, cortex and striatum computed, using the Kontron image analysis system.
- Figure 1 shows the effect of (i) vehicle; (ii) 128 mg/kg of clomethiazole dosed intraperitoneally (i.p.); and (iii) 30 mg/kg i.p. of compound (lb), on infarct volumes (assessed using tetrazolium histochemistry) after transient middle cerebral artery occlusion.
- Data are displayed as (mean + SEM) using absolute infarct volumes in mm 3 .
- ** signifies p ⁇ 0.01
- * signifies p ⁇ 0.05 in the t test.
- Figure 1 illustrates that compound (lb) exhibits significant neuroprotection at a dose of 30 mg/kg i.p. in the rat transient MCAo model. Clomethiazole at a dose of 128 mg/kg i.p. was found not to be effective in this model (see Sydserff, S.G. et al.,. Br. J. Pharmacol. 1995, 114, 1631-1635).
- MCA middle cerebral artery
- halothane anaesthesia (1.5% halothane in nitrous oxide: oxygen (70:30)
- a small craniectomy was made to expose the left MCA.
- the distal portion of the MCA was occluded by electrocoagulation.
- the incision site was sutured and anaesthetics withdrawn.
- Figure 2 shows that that compound (lb) exhibits significant neuroprotection at a dose of 60 mg/kg i.p. in the mouse permanent MCAo model.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Use of a compound of formula (I) wherein R1 is aryl; and R2 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for neuroprotection in a subject or for the treatment of cerebral ischaemia, central nervous system injury or eye diseases.
Description
CHEMICAL COMPOUNDS - III
The present invention relates primarily to neuroprotection and to the treatment of stroke and other cerebrovascular disorders.
Stroke and other acute brain injuries are major causes of mortality and morbidity in the adult population. Stroke is the third highest cause of death in major industrialised countries and the commonest cause of permanent disability. Each year, in the US and Europe, approximately 1 million people suffer an acute stroke. Between 25% and 35% of these patients die within the first three weeks, and of the survivors 25% to 50% will be totally dependant on family or institutional care for the rest of their lives. The incidence of stroke increases with age, roughly doubling with each passing decade, with 30% of persons aged over 65 years being affected.
The statistics for stroke translate into an annual incidence of 0.1 to 0.2% in the US and Europe, with the world- wide market for stroke estimated to be worth $3 billion in 1995 and projected to rise to $10 billion in 2005. There is an unmet medical need for a cytoprotective therapy for stroke.
No effective neuroprotectant therapy is presently available for cerebrovascular disorders. The only therapy currently licensed for the treatment of ischaemic stroke is Genetech's thrombolytic recombinant tissue plasminogen activator (Activase®, rtPA; Alteplase). Activase is indicated for the management of acute ischaemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment with Activase should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial haemorrhage by a cranial computerised tomography (CT) scan or other diagnostic imaging method sensitive for the presence of haemorrhage.
The mechanisms underlying the irreversible brain damage which occurs following ischaemia are complex. Many classes of compounds are currently under investigation as treatments for cerebrovascular disorders. Acute intervention with both cytoprotective (neuroprotective) and other thrombolytic agents is undergoing active investigation.
Cytoprotective neuroprotective therapy includes drugs that act to prevent cell death during ischaemia and reperfusion. These agents include calpain inhibitors, voltage-sensitive calcium- and sodium-channel antagonists, receptor-mediated calcium-channel antagonists [including N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMP A) antagonists], glutamate-synthesis inhibitors, glutamate-release antagonists, γ-aminobenzoic acid (GABA) antagonists, 5-HT (serotonin) receptor agonists, gangliosides, antioxidants, growth factors, antiapoptotic agents, and antiadhesion molecules (Silver, B., Weber, J., Fisher, M., Clin. Neuropharmacol. 1996, 19, 101-128).
Excitotoxicity is a major determinant of neuronal death following the induction of cerebral ischaemia. Repetitive cell firing, persistent depolarisation and induction of supra-normal ionic flux across excitable membranes can initiate fatal cellular compromise via a variety of synergistic mechanisms during hypoxic excitotoxicity. Control of the state of excitability of neurons depends upon the net balance of excitatory and inhibitory influences acting on that neurone.
In general, the primary excitatory influence impinging on neurones is mediated by the glutamatergic system, whilst primary inhibition is frequently determined by GABAergic innervation, since the main endogenous inhibitory amino acid in mammalian brain is GABA. Thus increasing the inhibitory effect of GABAergic innervation, and decreasing the excitatory influence of glutamate, will reduce the net excitation of a neurone. Reducing excitation will reduce the consequences of energy depletion due to hypoxia and promote the ability of the neurone to survive hypoxic cerebral ischaemia.
Relatively few of the drugs currently under investigation as neuroprotectants for the treatment of stroke and other cerebrovascular disorders are modulators of the endogenous inhibitory amino acid, GABA.
One class of molecules which apparently possess neuroprotective properties is the GABA uptake inhibitors such as CI-966, which was shown to be effective in a gerbil ischaemia model utilising global cerebral ischaemia of 5 min. duration (Phillis, J.W., Gen. Pharmacol. 1995, 26, 1061-1064).
The benzodiazepine receptor agonist diazepam has been shown to possess some neuroprotective properties (Karle, J., Witt, M. R., Nielsen, M., Brain Res. 1997, 765, 21- 29).
In rabbits with reversible spinal cord ischaemia, treatment with muscimol, a reference GABAA agonist, at 5 mg/kg significantly prolonged P50 time, where P50 represents the duration associated with 50% probability of resultant permanent paraplegia (Madden, K.P., Stroke, 1994, 25, 2271-2275).
Felbamate, an antiepileptic drug with inter alia GABA agonist properties, provided significant neuronal protection when administered both before and after ischaemia in all regions of the brain in the gerbil model of transient forebrain ischaemia. Protection was moderate when felbamate was used before ischaemia, but was highly significant when felbamate was given 30 min. after the insult. The structural protection with felbamate was very significant when used in the post-ischaemic period (Shuaib, A., Waqaar, T., Ijaz, M.S., Kanthan, R., Wishart, T., Howlett, W., Brain Res. 1996, 727, 65-70).
Piracetam is a derivative of GABA, and was the first commercially available nootropic drug. Although widely evaluated in the treatment of senile cognitive disorders and dyslexia, piracetam has also been assessed as a treatment for deficits associated with acute stroke. Data from a number of small, short term studies in patients treated within a few days of stroke suggest that piracetam is more effective than placebo for the treatment of functional deficits (Noble, S., Benfield, P., CNS Drugs 1998, 9, 497-511).
Some combination neuroprotectant therapies have been investigated in rodent ischaemia since the excitotoxic effects of glutamate can be blocked almost completely with GABA in cell culture, tissue slices, and in some animal models. On this basis a combination of muscimol and MK 801, an NMD A receptor antagonist, was investigated and shown to be effective (Lyden, P.D., Lonzo, L., Stroke 1994, 25, 189-196).
WO-A-99/25353 discloses the use of triazolo[4,3-b]pyridazine derivatives as benzodiazepine/GABAA modulators for the treatment of psychotic disorders and neurodegeneration.
WO-A-90/09174 discloses the use of the GABAergic agent Clomethiazole (chlormethiazole) in the prevention and/or treatment of neurodegeneration. Clomethiazole is thought to act through a GABAergic pathway, whereby it augments GABA's inhibitory effect on the CNS, giving the drug both hypnotic and neuroprotectant properties.
The clinical neuroprotectant profile of clomethiazole has been reviewed (Muckle, H., IDrugs 1999, 2, 184-193). A large-scale phase III trial has been completed in which clomethiazole was evaluated for its ability to reduce nerve damage in acute cerebrovascular ischaemia. A subgroup of patients who presented with large stroke, experienced a significant benefit. Of these (n = 545), 41% of treated patients were functionally independent after 90 days, compared to 30% of patients on placebo.
The effectiveness of this GABA modulator in rat (Snape, M.F., Baldwin, H.A., Cross, A.J., Green, A.R., Neuroscience 1993, 53, 837-844) and gerbil ischaemia (Cross, A.J., Jones, J.A., Baldwin, H.A., Green, A.R., Br. J. Pharmacol. 1991, 104, 406-411) has been demonstrated. The dose in the latter paradigm was 100 mg/kg, i.p.
Azetidine-1-carboxamides and the use of these compounds in the treatment of anxiety and all forms of epilepsy is described in International Patent Application No. PCT/GB99/00223.
There remains a medical need for new treatments for stroke and cerebrovascular disorders. The object of the present invention is to provide such treatments.
It has now been found that certain azetidine-1-carboxamides show unexpected neuroprotectant efficacy when compared to reference GABAergic agents. In particular, certain azetidine-1-carboxamides have been shown to potentiate the action of GABA in inhibiting neurones, and have also been shown to prevent the repetitive firing induced as a consequence of activation of glutamatergic mechanisms. Such compounds are found to be neuroprotective following acute cerebral ischaemia in rats and mice, and reduced ischaemia-induced CNS damage in in vivo models of focal ischaemia in both species.
According to the present invention, there is provided the use of a compound of formula (I)
(I) wherein: R1 is aryl; and R2 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof, in the manufacture of a medicament for neuroprotection in a subject or for the treatment of cerebral ischaemia, central nervous system injury or eye diseases.
Reference in the present specification to an "alkyl" group means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical. Where cyclic or acyclic the alkyl group is preferably Ci to Cj2, more preferably d to C8 (such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, isopentyl, hexyl, heptyl, octyl). It will be appreciated therefore that the term "alkyl" as used herein includes alkyl (branched or unbranched), alkenyl (branched or unbranched), alkynyl (branched or unbranched), cycloalkyl, cycloalkenyl and cycloalkynyl. In a preferred embodiment, a cyclic alkyl group is preferably C3 to 2, more preferably C5 to and an acyclic alkyl group is preferably Ci to do, more preferably Ci to C6, more preferably methyl, ethyl, propyl (n- propyl or isopropyl), butyl (n-butyl, isobutyl or tertiary-butyl) or pentyl (including n-pentyl and iso-pentyl), more preferably methyl.
Reference in the present specification to an "aryl" group means a mono or bicyclic aromatic group, such as phenyl or naphthyl.
The alkyl and aryl groups may be substituted or unsubstituted. In one embodiment, only the aryl group defined above as Rj and the alkyl group defined above as R2 may be substituted. Where substituted, there will generally be 1 to 3 substituents present, preferably 1 or 2 substituents. Substituents may include:
carbon containing groups such as alkyl aryl, arylalkyl (e.g. substituted and unsubstituted phenyl, substituted and unsubstituted benzyl); halogen atoms and halogen containing groups such as haloalkyl (e.g. trifluoromethyl); oxygen containing groups such as alcohols (e.g. hydroxy, hydroxyalkyl, (aryl)(hydroxy)alkyl), ethers (e.g. alkoxy, alkoxyalkyl, aryloxyalkyl), aldehydes (e.g. carboxaldehyde), ketones (e.g. alkylcarbonyl, alkylcarbonylalkyl, arylcarbonyl, arylalkylcarbonyl, arylcarbonylalkyl), acids (e.g. carboxy, carboxyalkyl), acid derivatives such as esters (e.g. alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl) and amides
(e.g. aminocarbonyl, mono- or dialkylaminocarbonyl, aminocarbonylalkyl, mono- or dialkylaminocarbonylalkyl, arylaminocarbonyl); nitrogen containing groups such as amines (e.g. amino, mono- or dialkylamino, aminoalkyl, mono- or dialkylaminoalkyl), azides, nitriles (e.g. cyano, cyanoalkyl), nitro; sulphur containing groups such as thiols, thioethers, sulphoxides and sulphones
(e.g. alkylthio, alkylsulfinyl, alkylsufonyl, alkylthioalkyl, alkylsulfmylalkyl, alkylsulfonylalkyl, arylthio, arylsulfinyl, arylsulfonyl, arylthioalkyl, arylsulfinylalkyl, arylsulfonylalkyl); and
heterocyclic groups containing one or more, preferably one,
heteroatom,
(e.g. thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, pyranyl, pyronyl, pyridyl, pyrazinyl, pyridazinyl, piperidyl, piperazinyl, morpholinyl, thionaphthyl, benzofuranyl, isobenzofuryl, indolyl, oxyindolyl, isoindolyl, indazolyl, indolinyl, 7- azaindolyl, isoindazolyl, benzopyranyl, coumarinyl, isocoumarinyl, quinolyl, isoquinolyl, naphthridinyl, cinnolinyl, quinazolinyl, pyridopyridyl, benzoxazinyl, quinoxadinyl, chromenyl, chromanyl, isochromanyl and carbolinyi).
Preferred substituents include alkyl, aryl, halo, or an halogen-containing group such as trifluoromethyl.
As used herein, the term "alkoxy" means alkyl-O- and "alkoyl" means alkyl-CO-.
As used herein, the term "halogen" means a fluorine, chlorine, bromine or iodine radical, preferably a fluorine or chlorine radical.
The compounds of formula (I) may exist in a number of diastereomeric and/or enantiomeric forms. Unless otherwise stated, reference in the present specification to "a compound of formula (I)" is a reference to all stereoisomeric forms of the compound and includes a reference to the unseparated stereoisomers in a mixture, racemic or non-racemic, and to each stereoisomer in its pure form.
In a preferred embodiment of the present invention, a compound of formula (I) is the (R - enantiomer of the compound of formula (I), substantially free of its (S)-enantiomer.
In the compounds of formula (I), preferably R1 is a substituted or unsubstituted aryl group selected from phenyl and naphthyl, more preferably R1 is a substituted phenyl or naphthyl, more preferably R1 is phenyl or naphthyl having 1 to 3 substituents and most preferably R1 is
phenyl or naphthyl having 1 or 2 substituents. In a preferred embodiment of the invention, R1 is a mono- or di-substituted phenyl group, preferably a mono-substituted phenyl group.
Where R1 is napthyl, it is preferred that R1 is 2-naphthyl.
The preferred substituent groups are selected from halo (preferably fluoro and chloro), trifluoromethyl and tertiary butyl, and more preferably from fluoro, chloro and trifluoromethyl.
Where R1 is a phenyl having 1 substituent, the phenyl group is preferably para- or meta-substituted. Where R1 is a phenyl having 2 substituents, the phenyl group is preferably 2,3-disubstituted, 2,4-disubstituted, 3,4-disubstituted or 3,5-disubstituted, preferably 3,4- disubstituted.
Where R1 is disubstituted, it is preferred that R1 is substituted by two halo groups, the same or different, or by one halo group and one trifluoromethyl group. More preferably, R1 is dichloro-, difluoro-, chloro-fluoro- or fluoro-trifluoromethyl-substituted.
The R1 groups are preferably selected from 4-chlorophenyl, 4-fluorophenyl, 4- (trifluoromethyl)phenyl, 3-(trifluoromethyl)phenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 3-chloro-4-fluorophenyl, 4-chloro-3-fluorophenyl, 3-fluoro-4-(trifluoromethyl)phenyl, 4- fluoro-3-(trifluoromethyl)phenyl and 3-chloro-5-fluorophenyl.
In one embodiment of the present invention R is alkyl, preferably selected from Cι-8 alkyl, more preferably from alkenyl, alkynyl, hydroxyalkyl, alkoxyalkyl and unsubstituted saturated cyclic and acyclic hydrocarbyl, and more preferably from propyl, 2-propenyl, 2-propynyl and 2-hydroxypropyl.
Particularly preferred compounds are as follows:-
In a preferred embodiment of the present invention, the compound of formula (I) is 3-(4- (trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine-l-carboxamide (la) or a pharmaceutically acceptable salt or prodrug thereof. In a particularly preferred embodiment of the present invention, the compound of formula (I) is the (r?)-enantiomer of 3 -(4-(trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine- 1 -carboxamide (lb), substantially free of its (S)-enantiomer, or a pharmaceutically acceptable salt or prodrug thereof.
Compound lb
According to a further aspect of the present invention there is provided a method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of the compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
According to a further aspect of the present invention there is provided a method of treatment of cerebral ischaemia, central nervous system injury or eye diseases comprising administration to a subject in need of such treatment an effective dose of the compound of formula (I), or a pharmaceutically acceptable salt or prodrug thereof.
The present invention may be employed in respect of a human or animal subject, more preferably a mammal, more preferably a human subject.
As used herein, the term "treatment" as used herein includes prophylactic treatment.
As used herein, the term "prodrug" means any pharmaceutically acceptable prodrug of the compound of formula (I). For example, the compound of formula (I) may be prepared in a prodrug form wherein a free -OH group is derivatised (for example, via an ester, amide or phosphate bond) with a suitable group (the group may contain, for example, an alkyl, aryl, phosphate, sugar, amine, glycol, sulfonate or acid function) which is suitably labile so as it will be removed / cleaved (eg. by hydrolysis) to reveal the compound of formula (I) sometime after administration or when exposed to the desired biological environment.
As used herein, the term "pharmaceutically acceptable salt" means any pharmaceutically acceptable salt of the compound of formula (I). Salts may be prepared from pharmaceutically acceptable non-toxic acids and bases including inorganic and organic acids and bases. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethenesulfonic, dichloroacetic, furnaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic,
lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like. Particularly preferred are hydrochloric, hydrobromic, phosphoric, sulfuric and methanesulfonic acids, and most particularly preferred is the methanesulfonate salt. Acceptable base salts include alkali metal (e.g. sodium, potassium), alkaline earth metal (e.g. calcium, magnesium) and aluminium salts.
As used herein, the term "substantially free of its (S)-enantiomer" means that the medicament or therapeutic composition comprising the compound of formula (I) used according to the present invention contains a greater proportion of the (R)-enantiomer of the compound of formula (I) in relation to the (S)-enantiomer of the compound of formula (I). In a preferred embodiment of the present invention the term "substantially free of its (S)-enantiomer", as used herein, means that the composition contains at least 90 % by weight of the (i?)-enantiomer and 10 % by weight or less of the (S)-enantiomer. In a further preferred embodiment, the term "substantially free of its (S)-enantiomer" means that the composition contains at least 99 % by weight of the K)-enantiomer and 1 % or less of the (S)-enantiomer. In another preferred embodiment, the term "substantially free of its (S)-enantiomer" means that the composition contains 100 % by weight of the (R)- enantiomer. The above percentages are based on the total amount of compound of formula (I) present in the medicament or therapeutic composition used according to the present invention.
The diseases, disorders and medical treatments/procedures to which the present invention is directed are: Cerebral Ischaemia, including transient ischaemic attack, stroke (thrombotic stroke, ischaemic stroke, embolic stroke, haemorrhagic stroke, lacunar stroke), subarachnoid haemorrhage, cerebral vasospasm, neuroprotection for stroke, peri-natal asphyxia, drowning, carbon monoxide poisoning, cardiac arrest and subdural haematoma; Central Nervous System Injury, including traumatic brain injury, neurosurgery (surgical trauma), neuroprotection for head injury, raised intracranial pressure, cerebral oedema, hydrocephalus and spinal cord injury; and
Eye Diseases, including drug-induced optic neuritis, cataract, diabetic neuropathy, ischaemic retinopathy, retinal haemorrhage, retinitis pigmentosa, acute glaucoma, chronic glaucoma, macular degeneration, retinal artery occlusion and retinitis.
Additionally, the compound of formula (I) may also be used to potentiate the effects of other treatments, for example to potentiate the neuroprotective effects of brain derived nerve growth factor.
The invention is particularly directed to the treatment of cerebral ischaemia and central nervous system injury. The invention is also particularly directed to the treatment of post- asphyxial brain damage in new-born subjects.
The compound of formula (I) may be used in combination with one or more additional drugs useful in the treatment of the disorders mentioned above, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.
Compounds of formula (I) may be prepared according to the reaction scheme (where P is a
1 ^ nitrogen protecting group). R and R are as previously defined. The 3-aryl-3-azetidinol (LU) may be formed by treatment of the ketone (II) with an organometallic reagent such as an aryllithium or an arylmagnesium halide. Removal of the hydroxyl group to give the 3- arylazetidine (TV) may be effected by several methods including, for example, catalytic hydrogenolysis; treatment with lithium or sodium and ammonia; conversion to the xanthate by treatment with carbon disulphide, methyl iodide and base, followed by tin-mediated reduction; and conversion to the 3-aryl-3-chloroazetidine analogue using an alkylsulfonyl chloride and a base, followed by a reductive dechlorination using sodium, lithium or nickel. Formation of the azetidine (V) is achieved by reaction of (IV) with a suitable nitrogen deprotection agent. For example, if P is a diphenylmethyl group, then deprotection may be carried out by either catalytic transfer hydrogenation (e.g. ammonium formate and palladium catalyst) or by treatment with 1-chloroethyl chloroformate followed by methanol. The urea (I) is formed by reaction of azetidine (V) with an N-alkylisocyanate or an N-alkylcarbamoyl chloride and a base such as triethylamine or potassium carbonate. Alternatively, the urea may
be prepared directly from the azetidine (TV) without isolation of an intermediate such as the secondary amine (V). For example, when P is a diphenyknethyl group, azetidine (IV) may be treated with phosgene followed by amme R NH to give urea (I) directly.
Reaction Scheme
π rπ
V TV
I
The invention further provides a pharmaceutical composition comprising an effective amount of the compound of formula (I) in combination with a pharmaceutically acceptable carrier or excipient and a method of making such a composition comprising combining an effective amount of the compound of formula (I) with a pharmaceutically acceptable carrier or excipient.
To further increase efficacy, the composition may contain components such as dextrans or cyclodextrins or ether derivatives thereof, which aid stability and dispersion, and decrease metabolism of the active ingredient.
For compositions in which the pharmaceutically acceptable carrier comprises a cyclodextrin or an ether derivative thereof, the active ingredient is intimately mixed with an aqueous solution of the cyclodextrin or ether derivative thereof, with optional addition of further pharmaceutically acceptable ingredients before, during or after said mixing. The thus obtained solution is optionally lyophilized, and the lyophilized residue is optionally reconstituted with water.
In an embodiment of the present invention, the composition further comprises a buffer system, an isotonizing agent and water.
Compounds of formula (I) may be administered in a form suitable for oral use, for example a tablet, capsule, aqueous or oily solution, suspension or emulsion; for topical use including transmucosal and transdermal use, for example a cream, ointment, gel, aqueous or oil solution or suspension, salve, patch or plaster; for nasal use, for a example a snuff, nasal spray or nasal drops; for vaginal or rectal use, for example a suppository; for administration by inhalation, for example a finely divided powder or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oil solution cr suspension. In general the above compositions may be prepared in a conventional manner using conventional excipients, using standard techniques well known to those skilled in the art of pharmacy. Preferably, the compound is administered orally.
For oral administration, the compounds of formula (I) will generally be provided in the form of tablets or capsules or as an aqueous solution or suspension.
Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose,
while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.
For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of formula (I) will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous suspensions may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.
It will be appreciated that the dosage levels used may vary over quite a wide range depending upon the compound used, the severity of the symptoms exhibited by the patient and the patient's body weight.
The invention will now be described in detail with reference to the following examples. It will be appreciated that the examples are intended to illustrate and not to limit the scope of the present invention.
EXAMPLES
Synthetic Examples l-(Diphenylmethyl)-3-azetidinol (2)
The compound (2) was prepared according to the method of Anderson and Lok (J Org. Chem. 1972, 37, 3953, the disclosure of which is incorporated herein by reference), m.p. 111- 112 °C (lit. m.p. 113 °C).
1 -Diphenylmethyl-3-azetidinone (3)
Dimethyl sulfoxide (0.36 mL, 5 mmol) was added dropwise to a stirred solution of oxalyl chloride (0.40 mL, 4.6 mmol) in dichloromethane (20 mL) at -78 °C under an argon atmosphere. The mixture was stirred for 10 minutes then a solution of l-(diphenylmethyl)-3- azetidinol (1.0 g, 4.2 mmol) in dichloromethane (20 mL) was added dropwise. The mixture was warmed to -50 °C and stirred for 30 minutes. Triethylamine (2.9 mL, 21 mmol) was added and the mixture warmed to room temperature. After 1 hour, water (50 mL) was added and the mixture extracted with dichloromethane (4 x 50 mL). The combined organic exfracts were washed (brine), dried (Na2SO4) and concentrated in vacuo to give l-diphenylmethyl-3- azetidinone (3) as a pale yellow crystalline solid (1.0 g, 99 %) (lit. (S.S. Chatterjee and A. Shoeb, Synthesis, 1973,153) m.p. 82°C).
3-(4-ChIorophenyl)-l-(diphenylmethyl)-3-azetidinol (4)
To a stirred solution of 4-chlorophenylmagnesium bromide (9.1 mL, 1.0M in diethyl ether) in diethyl ether (80 mL) at -78 °C under an argon atmosphere was added compound 3 (1.8 g, 7.6 mmol) in diethyl ether (50 mL) dropwise over 20 minutes. The reaction mixture was stirred at -78 °C for 2 hours, then slowly warmed to room temperature with stirring over 18 hours. The reaction mixture was then partitioned between aqueous ammonium acetate solution (50 mL) and diethyl ether (50 mL). The aqueous layer was extracted with diethyl ether (3 x 50 mL) and the combined organic extracts were washed (water, brine), dried (Na SO ), filtered and concentrated in vacuo to give the crude product as a pale yellow viscous oil in quantitative yield. A sample purified for analysis by column chromatography on silica gel using 15-30% ethyl acetate-hexane as eluent and subsequent crystallisation from hexane gave 3-(4-
chlorophenyl)-l-(diphenylmethyl)-3-azetidinol (4), m.p. 108°C. Found: C, 75.42; H, 5.79; N, 3.98. C22H20C1NO requires C, 75.53; H, 5.76; N, 4.00%.
O-(3-(3-(4-Chlorophenyl)-l-diphenylmethyl))azetidinyl)-S-methyldithiocarbonate (5)
To a stirred suspension of sodium hydride (0.4 g of a 60% suspension in mineral oil, 10.4 mmol) (prewashed with hexane) in THF (80 mL) was added dropwise a solution of compound 4 (1.7 g, 4.9 mmol) in THF (80 mL). The mixture was stirred for 3 hours then carbon disulphide (17.6 mL, 0.29 mol) and methyl iodide (6.1 mL, 0.1 mol) were added dropwise. The mixture was stirred at room temperature for 15 hours and then heated to 50 °C while the solvent was removed in a stream of argon. When the volume of the mixture was reduced by half, the mixture was concentrated in vacuo to an approximate volume of 20 mL and then partitioned between water and diethyl ether. The organic layer was washed with water and then brine, dried (Na2SO ), filtered and concentrated in vacuo. The crude product was crystallised from hexane to give 0-(3-(3-(4-chlorophenyl)- 1 -diphenylmethyl))azetidinyl)- S-methyldithiocarbonate (5) (2.06g, 96%).
3-(4-Chlorophenyl)-l-(diphenylmethyl)azetidine (6)
To a stirred solution of tributyltin hydride (1.8 mL, 6.9 mmol) in dry toluene (40 mL) at reflux under an argon atmosphere was added dropwise, over 1 hour, a solution of compound 5 (2.0 g, 4.6 mmol) in toluene (40 mL). The mixture was heated under reflux for a further 2 hours then was concentrated in vacuo. The residue obtained was purified by flash column chromatography on silica gel using hexane and then 10% ethyl acetate-hexane as eluent. The product was recrystallised twice from hexane to give 3-(4-chlorophenyl)-l- (diphenylmethyl)azetidine (6) (0.4 g, 34%) m.p. 82 °C. Found: C, 78.94; H, 6.06; N, 4.14. C22H20C1N requires C, 79.15; H, 6.04; N, 4.20%.
3-(4-Chlorophenyl)azetidine (7)
To a solution of compound 6 (0.36 g, 1.1 mmol) in 1,2-dichloroethane (10 mL) containing proton sponge (0.02 g), cooled in an ice-water bath under an argon atmosphere, was added
dropwise 1-chloroethyl chloroformate (0.3 mL, 3.1 mmol). The resultant solution was boiled at reflux for 4 hours, cooled and was concentrated in vacuo. The residue obtained was mixed with methanol (10 mL) and heated under reflux for 2 hours, then cooled and concentrated in vacuo to give the hydrochloride salt of 3-(4-chlorophenyl)azetidine (7) which was used without further purification.
Example 1. 3-(4-Chlorophenyl)-N-(2-propenyl)azetidine-l-carboxamide (8)
To the hydrochloride salt of 3-(4-chlorophenyl)azetidine (7) (approximately 1.1 mmol) in ethanol (10 mL) stirred at 0°C was added sequentially and dropwise allyl isocyanate (0.15 mL, 1.7 mmol) followed by triethylamine (0.3 mL, 2.2 mmol). After 20 minutes the reaction mixture was partitioned between aqueous ammonium chloride and ether. The organic layer was washed (water and then brine), dried (Na SO4), filtered and concentrated in vacuo to give a crude product. The product obtained was purified by column chromatography on silica gel using 20% ethyl acetate-hexane as eluent to give 3-(4-chlorophenyl)-N-(2-propenyl)azetidine- 1-carboxamide (8) which was recrystallised from cyclohexane/toluene (0.16 g, 61%), m.p. 112 °C. Found: C, 62.20; H, 6.23; N, 11.40. Cι3H,5ClN2O requires C, 62.28; H, 6.03; N, 11.17%.
3-(4-tert-Butylphenyl)-l-diphenylmethyl-3-azetidinol (9)
To a stirred solution of 4-tert-butylphenylmagnesium bromide (11.5 mL, 2.0M (Et2O)) in toluene (50 mL) at -78°C under argon, was added, dropwise, a solution of 1-diphenylmethyl- 3-azetidinone (3) (5.0 g) in toluene (100 mL) over 30 minutes. The mixture was stirred for 4 hours at -78°C then warmed to room temperature and partitioned between aqueous ammomum chloride solution (50 mL) and diethyl ether (3 x 50 mL). The combined organic fractions were washed (water, brine), dried (Na SO4) and concentrated in vacuo. Recrystallisation from cyclohexane gave 3-(4-tert-butylphenyl)-l-diphenylmethyl-3- azetidinol (9) (6.23 g), m.p. 168-169°C (cyclohexane). Found: C. 83.68; H, 7.97; N, 3.72. C26H29NO requires C, 84.06; H, 7.87; N, 3.77%.
3-(4-tert-ButylphenyI)-3-chloro-l-(diphenylmethyl)azetidine (10)
To a stirred solution of compound (9) (6.23 g) and N,N-diisopropylethylamine (3.5 mL) in dichloromethane (100 mL) at 0°C was added, dropwise, methanesulfonyl chloride (1.4 mL). The mixture was stirred at 0°C for 18 hrs, then washed (water, brine), dried (Na2SO4) and concentrated in vacuo. The crude product was recrystallised from hexane to give 3-(4-tert- butylphenyl)-3-chloro-l-(diphenylmethyl)azetidine (10) (4.73 g) m.p. 145°C (hexane). Found: C, 80.30; H, 7.05; N, 3.64. C26H28C1N requires C, 80.08; H, 7.24; N, 3.59%.
3-(4-tert-Butylphenyl)-l-(diphenylmethyl)azetidine (11)
To a stirred suspension of Raney Nickel (8.6 g, wet slurry) in tertiary butanol (50 mL) and toluene (50 mL) was added a solution of 3 -(4-tert-butylphenyl)-3 -chloro- 1- (diphenylmethyl)azetidine (10) (4.73 g) in toluene (10 mL). The mixture was heated to 80°C for 6 hours, cooled to room temperature and filtered through kieselguhr. The filtrate was concentrated in vacuo and partitioned between diethyl ether (3 x 50 mL) and aqueous potassium carbonate solution (50 mL). The combined organic extracts were washed (water, brine), dried (Na SO4), concentrated in vacuo and purified by flash column chromatography (10%) ethyl acetate/hexane) on silica. Recrystallisation from methanol gave 3-(4-tert- butylphenyl)-l-(diphenylmethyl)azetidine (11) (3.40 g), m.p. 95°C (methanol). Found: C, 87.84; H, 8.17; N, 3.92. C26H29N requires C, 87.84; H, 8.22; N, 3.94%.
Example 2. 3-(4-tert-Butylphenyl)-N-(2-propenyl)azetidine-l-carboxamide (12)
To a stirred solution of 3-(4-tert-butylphenyl)-l-(diphenylmethyl)azetidine (11) (1.0 g) in dichloromethane (10 mL) at 0°C was added dropwise a solution of 20% phosgene in toluene (2.5 mL) The mixture was stirred for 90 minutes then concentrated in vacuo. To the concentrate was added dichloromethane (10 mL) and to this solution at 0°C was added, dropwise, with stirring, allylamine (0.8 mL). The mixture was stirred for 18 hrs at room temperature, diluted with dichloromethane (30 mL), washed (water, brine), dried (Na2SO4), concentrated in vacuo and purified by flash column chromatography (50% ethyl acetate- hexane) to give 3-(4-tert-butylphenyl)-7V-(2-propenyl)azetidine-l-carboxamide (12) (0.21 g), m.p. 98-99°C (diisopropyl ether). Found: C, 74.95; H, 8.97; N, 10.25. Cj7H24N2O requires C, 74.96; H, 8.88; N, 10.28%.
Example 3. 3-(4-tert-Butylphenyl)-N-(2-propynyl)azetidine-l-carboxamide (13)
To a stirred solution of 3-(4-tert-butylphenyl)-l-(diphenylmethyl)azetidine (11) (0.5 g) in dichloromethane (5 mL) at 0°C was added dropwise a solution of 20% phosgene in toluene (0.8 mL) The mixture was stirred for 90 minutes then concentrated in vacuo. To the concentrate was added dichloromethane (5 mL) and to this solution at 0°C was added dropwise with stirring propargylamine (0.24 mL). The mixture was stirred for 18 hrs at room temperature, diluted with dichloromethane (20 mL), washed (water, brine), dried (Na SO4) and concentrated in vacuo. Trituration with diethyl ether (2 mL) gave 3-(4-tert-butylphenyl)- N-(2-propynyl)azetidine-l-carboxamide (13) (0.14 g), m.p. 141 °C (diethyl ether). Found: C, 75.40; H, 8.19; N, 10.38. d7H22N2O requires C, 75.52; H, 8.20; N, 10.36%.
Example 4. (R)-3-(4-tert-ButyIphenyl)-7V-(2-hydroxypropyl)azetidine-l-carboxamide (14)
To a stirred solution of 3-(4-tert-butylphenyl)-l-(diphenylmethyl)azetidine (11) (0.50 g) in dichloromethane (5 mL) at 0°C was added dropwise a solution of 20% phosgene in toluene (0.8 mL). The mixture was stirred for 90 minutes then concentrated in vacuo. To the concentrate was added dichloromethane (5 mL) and to this solution at 0°C was added dropwise with stirring (R)-l-amino-2-propanol (0.25 mL). The mixture was stirred for 18 hrs at room temperature, diluted with dichloromethane (20 mL), washed (water, brine), dried (Na2SO4) concentrated in vacuo and purified by flash column chromatography (10% methanol-ethyl acetate) to give (R)-3-(4-tert-butylphenyl)-N-(2-hydroxypropyl)azetidine-l- carboxamide (14) (0.35 g), m.p. 96-97°C (diisopropyl ether). Found: C, 69.59; H, 8.74; N, 9.23. Cι7H26N2O requires C, 70.31; H, 9.02; N, 9.64%.
3-(4-Fluorophenyl)-l-diphenylmethyl-3-azetidinoI (15)
To a stirred solution of 4-fluorophenylmagnesium bromide (7.0 mL, 1.0M (Et O)) in toluene (20 mL) at -78°C under argon, was added, dropwise, a solution of l-diphenylmethyl-3-
azetidinone (3) (1.4 g) in toluene (30 mL) over 30 minutes. The mixture was stirred for 4 hours at -78°C then warmed to room temperature and partitioned between aqueous ammonium chloride solution (50 mL) and diethyl ether (3 x 20 mL). The combined organic fractions were washed (water, brine), dried (Na SO ) and concentrated in vacuo. Purification by flash column chromatography (20% ethyl acetate, hexane) gave 3-(4-fluorophenyl)-l- diphenylmethyl-3-azetidinol (15) (1.82 g). To a stirred solution of the free base (1.82 g) in ether (5 mL) was added dropwise a solution of oxalic acid (0.49 g) in acetone (1 mL). The mixture was stirred for 5 minutes then filtered to give the oxalate salt hemihydrate (2.23 g), m.p. 75°C (acetone). Found: C, 66.71; H, 5.34; N, 3.04. C2 H 2FNO5.0.5H2O requires C, 66.67; H, 5.32; N, 3.17%.
3-(4-FIuorophenyl)-3-chloro-l-(diphenylmethyl)azetidine (16)
To a stirred solution of 3-(4-fluorophenyl)-l-diphenylmethyl-3-azetidinol (15) (4.0 g) and N,N-diisopropylethylamine (3.2 mL) in dichloromethane (100 mL) at 0°C was added, dropwise, methanesulfonyl chloride (1.25 mL). The mixture was stirred at 0°C for 18 hrs, then washed (water, brine) and dried (Na SO4) and concentrated in vacuo. The crude product was recrystallised from hexane to give 3-(4-fluorophenyl)-3-chloro-l- (diphenylmethyl)azetidine (16) (2.2 g), m.p. 108-109°C (hexane). Found: C, 75.13; H, 5.46; N, 3.93. C22H19C1FN requires C, 75.10; H, 5.44; N, 3.98%.
3-(4-Fluorophenyl)-l-(diphenylmethyl)azetidine (17)
To a stirred suspension of Raney Nickel (2.0 g, wet slurry) in tertiary butanol (10 mL) and toluene (50 mL) was added a solution of 3-(4-fluorophenyl)-3-chloro-l- (diphenylmethyl)azetidine (16) (1.9 g) in toluene (20 mL). The mixture was heated to 80°C for 6 hours, cooled and filtered through kieselguhr. The filtrate was concentrated in vacuo and partitioned between diethyl ether (3 x 30 mL) and aqueous potassium carbonate solution (50 mL). The combined organic extracts were washed (water, brine), dried (Na2SO4), and concentrated in vacuo. Recrystallisation from diisopropyl ether gave 3-(4-fluorophenyl)-l- (diphenylmethyl)azetidine (17) (1.5 g), m.p. 65-66°C (diisopropyl ether). Found: C, 83.25; H, 6.35; N, 4.41. C22H20FN requires C, 83.25; H, 6.35; N, 4.41%.
Example 5. 3-(4-Fluorophenyl)-N-(2-propenyl)azetidine-l-carboxamide (18)
To a stirred solution of 3-(4-fluorophenyl)-N-(diphenylmethyl)azetidine (17) (0.67 g) in dichloromethane (5 mL) at 0°C was added dropwise a solution of 20% phosgene in toluene (2.5 mL). The mixture was stirred for 90 minutes then concentrated in vacuo. To the concentrate was added dichloromethane (5 mL) and to this solution at 0°C was added, dropwise, with stirring, allylamine (0.5 mL). The mixture was stirred for 18 hrs at room temperature, diluted with dichloromethane (20 mL), washed (water, brine), dried (Na2SO ) and concentrated in vacuo. Recrystallisation from diisopropyl ether gave 3-(4-fluorophenyl)- N-(2-propenyl)azetidine-l -carboxamide (18) (0.30g), m.p. 119-120°C (diisopropyl ether). Found: C, 66.61; H, 6.37; N, 11.74. C13Hι5FN2O requires C, 66.65; H, 6.45; N, 11.95%.
Example 6. 3-(4-FIuorophenyI)-N-(2-propynyl)azetidine-l-carboxamide (19)
To a stirred solution of 3-(4-fluorophenyl)-l-(diphenylmethyl)azetidine (17) (0.38 g) in dichloromethane (5 mL) at 0°C was added dropwise a solution of 20% phosgene in toluene
(1.4 mL). The mixture was stirred for 90 minutes then concentrated in vacuo. To the concentrate was added dichloromethane (5 mL) and to this solution at 0°C was added, dropwise, with stirring propargylamine (0.3 mL). The mixture was stirred for 18 hrs at room temperature, diluted with dichloromethane (20 mL), washed (water, brine), dried (Na2SO ) and concentrated in vacuo. The crude material was purified by flash column chromatography
(50% ethyl acetate hexane) and then crystallised from diisopropyl ether to give 3-(4- fluorophenyl)-N-(2-propynyl)azetidine- 1 -carboxamide ( 19) (0.14g), m.p. 141 °C (diisopropyl ether). Found: C, 67.32; H, 5.65; N, 11.93. Cι3H13FN2O requires C, 67.23; H, 5.64; N,
12.06%.
Example 7. (R)-3-(4-Fluorophenyl)-Λ/-(2-hydroxypropyl)azetidine-l-carboxamide (20)
To a stirred solution of 3-(4-fluorophenyl)-l-(diphenylmethyl)azetidine (17) (0.35 g) in dichloromethane (5 mL) at 0°C was added dropwise a solution of 20% phosgene in toluene (1.2 mL). The mixture was stirred for 90 minutes then concentrated in vacuo. To the concentrate was added dichloromethane (5 mL) and to this solution at 0°C was added dropwise with stirring (R)-l-amino-2-propanol (0.2 mL). The mixture was stirred for 18 hrs
at room temperature,diluted with dichloromethane (20 mL), washed (water, brine), dried (Na2SO ) and concentrated in vacuo. The crude product was purified by flash column chromatography (10% methanol-ethyl acetate) to give (R)-3-(4-fluorophenyl)-N-(2- hydroxypropyl)azetidine-l -carboxamide (20) (0.21g), m.p. 104-105 °C (toluene/ethanol). Found: C, 61.93; H, 6.97; N, 10.9. Cι3H17FN2O2 requires C, 61.89; H, 6.79; N, 11.10%.
Example 8. (3-(4-Chlorophenyl)-N-(2-propynyl)azetidine-l-carboxamide (21)
This compound was prepared from 3-(4-chlorophenyl-l-(diphenylmethyl)azetidine (6) and propargylamine using the procedure outlined in Example 3, m.p. 160 °C (diethyl ether). Found C, 62.85; H, 5.38; N, 10.89 C13H13ClN2O requires C, 62.78; H, 5.27; N, 11.26%.
Example 9. (R)-3-(4-ChlorophenyI)-N-(2-hydroxypropyl)azetidine-l-carboxamide (22)
This compound was prepared from compound (6) and (R)-l-amino-2-propanol using the procedure outlined in Example 4, m.p. 92-93 °C (diethyl ether-toluene). Found: C, 58.97; H, 6.38; N. 9.96. C13Hι7ClN2O2.0.2PhCH3, requires C, 60.23; H, 6.48; N, 9.76%.
Example 10: (S)-3-(4-Fluorophenyl)-N-(2-hydroxypropyI)azetidine-l-carboxamide (23)
This compound was prepared from compound (17) and (S)-l-amino-2-propanol using the procedure described for compound (20). m.p. 102-104°C. Found: C, 61.94; H, 6.72; N, 11.1. C13H17FN2O2 requires C, 61.89; H, 6.79; N, 11.10%.
3-(3,4-Dichlorophenyl)-l-(diphenylmethyl)azetidin-3-ol (24)
This compound was prepared from compound (3) and 3,4-dichlorophenylmagnesium bromide using the procedure described for compound (4).
3-(3,4-Dichlorophenyl)-3-chloro-l-(diphenylmethyl)azetidine (25)
This compound was prepared from compound (24) using the procedure described for compound (10).
3-(3,4-DichlorophenyI)-l-(diphenylmethyl)azetidine (26)
This compound was prepared from compound (25) using the procedure described from compound (11).
Example 11. 3-(3,4-Dichlorophenyl)-iV-(2-propynyI)azetidine carboxamide (27)
This compound was prepared from compound (26) and propargylamine using the procedure described for compound (12). m.p. 105.5-107.5°C.
Example 12. (R)-3-(3,4-Dichlorophenyl)-N-(2-hydroxypropyl)azetidine carboxamide (28)
This compound was prepared from compound (26) and (i?)-l-amino-2-propanol using the procedure described for compound (12). m.p. 123-125°C. Found: C, 51.58; H, 5.33; N, 9.26. Cι3Hι6Cl2N2O2 requires C, 51.50; H, 5.32; N, 9.24%.
Example 13. (S)-3-(3,4-Dichlorophenyl)-N-(2-hydroxypropyl)azetidine carboxamide (29)
This compound was prepared from compound (26) and (S)-l-amino-2-propanol using the procedure described for compound (12). m.p. 123-125°C. Found: C, 51.47; H, 5.30; N, 9.18. Cι3H16Cl2N2O2 requires C, 51.50; H, 5.32; N, 9.24%.
3-(4-(Trifluoromethyl)phenyl)-l-(diphenylmethyl)azetidin-3-ol (30)
This compound was prepared from compound (3) and 4-(trifluoromethyl)phenylmagnesium bromide using the procedure described for compound (4).
3-Chloro-3-(4-(trifluoromethyl)phenyl)-(diphenylmethyl)azetidine (31)
This compound was prepared from compound (30) using the procedure described for compound (10).
3-(4-(Trifluoromethyl)phenyl)-l-(diphenylmethyl)azetidine (32)
This compound was prepared from compound (31) using the procedure described for compound (11).
Example 14. (R)-3-(4-(Trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine carboxamide (33)
This compound was prepared from compound (32) and (R)-l-amino-2-propanol using the procedure described for compound (12). m.p. 107-108°C. Found: C, 54.78; H, 5.75; N, 9.01. C]4H17F3N2O2.0.25 H2O requires C, 54.81; H, 5.71, N, 9.13%.
Example 15. (S)-3-(4-(Trifluoromethyl)phenyl)-7V-(2-hydroxypropyl)azetidine carboxamide (34)
This compound was prepared from compound (32) and (S)-l-amino-2-propanol using the procedure described for compound (12). m.p. 107-108°C. Found: C, 54.75; H, 5.68; N, 9.09. Cι4H17F3N2O2.0.25 H2O requires C, 54.81; H, 5.71; N, 9.13%.
Example 16. 3-(4-(Trifluoromethyl)phenyl)-N-(2-propynyl)azetidine-l-carboxamide (35)
This product was prepared from compound (32) and propargylamine using the procedure described for compound (12). m.p. 151-155°C.
3-(3-(Trifluoromethyl)phenyl)-l-(diphenylmethyl)azetidin-3-ol (36)
This compound was prepared from compound (3) and 3-(trifluoromethyl)phenylmagnesium bromide using the procedure described for compound (4).
3-Chloro-3-(3-(trifluoromethyl)phenyl)-(diphenylmethyl)azetidine (37)
This compound was prepared from compound (32) using the procedure described for compound (10).
3-(3-(TrifluoromethyI)phenyl)-l-(diphenylmethyl)azetidine (38)
This compound was prepared compound (37) using the procedure described for compound (11).
Example 17. (R)-3-(3-(Trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine carboxamide (39)
This compound was prepared from compound (38) and (R)-l-amino-2-propanol using the procedure described for compound (12). m.p. 81-82°C.
Example 18. (S)-3-(3-(Trifluoromethyl)phenyI)-N-(-2-hydroxypropyI)azetidine carboxamide (40)
This compound was prepared from compound (38) and (S)-l-amino-2-propanol using the procedure described for compound (12). m.p. 80-82°C.
Example 19. 3-(3-(Trifluoromethyl)phenyl)-N-(2-propynyl)azetidine- 1 -carboxamide (41)
This product was prepared from compound (38) and propargylamine using the procedure described for compound (12). m.p. 121°C.
Example 20. 3-(4-(Trifluoromethyl)phenyI)-N-azetidine-l-carboxamide (42)
To a solution of 3-(4-(Trifluoromethyl)phenyl)-l-(diphenylmethyl)azetidine (32) (8.2 mmol) in dichloromethane (20 mL) at 0°C, was added a solution of phosgene (1.75M in toluene, 10.2 mmol). The reaction mixture was stiπed at room temperature for 90 minutes, concentrated in vacuo, then redissolved in THF (25 mL), cooled to 0°C and treated with ammonium hydroxide (12.5 mL). The reaction was stirred for 16 h, then water (80 mL) and ethyl acetate (100 mL) were added and the layers were separated. The aqueous layer was extracted with ethyl acetate (2 x 100 mL), combined organic layers washed with brine (60 mL), dried (Na2SO4) and concentrated in vacuo. The residue was triturated using ethyl acetate (60 mL) to a solid (1.64 g, 81%), mp. 207.5-208.5-°C (ethyl acetate). Found: C, 54.51 ; H, 4.59; N, 11.41. C14H17ClN2O2 requires: C, 54.10; H, 4.54; N, 11.47.
Examples 21 to 84 - See Table 1
These products were prepared using the procedure described for compound 12.
Table 1
Footnotes for Table 1 :
Footnote a: IR: 3373, 3316, 2923, 2855, 1639, 1620, 1557, 1488, 1462, 1434, 1378, 1304, 1153, 815 cm"1. Footnote b: IR: 3500, 3429, 3346, 3274, 2925, 2854, 1614, 1556, 1466, 1420, 1407, 1052, 824, 536 cm"1. Footnote c: IR: 3414, 3320, 3253, 2925, 2855, 1606, 1544, 1492, 1460, 1376, 1316, 1092,
822, 751, 705 cm"1. Footnote d: IR: 3340, 3166, 2923, 2854, 1650, 1613, 1493, 1460, 1378, 1303, 1098, 820 cm"1.
Footnote e: IR: 3310, 2964, 2878, 1632, 1538, 1494, 1482, 1462, 1398, 1328, 1093, 1015,
823, 529 cm"1. Footnote f: compound (102) was made by the oxidation of compound (33), by methods known to those skilled in the art. Footnote g: compound (104) was made from compound (102) by methods known to those skilled in the art.
Testing Procedures
Rat transient middle cerebral artery occlusion (MCAo) ischaemia model
This model of middle cerebral artery occlusion used relies on an intraluminal filament technique in the rat (Zhao Q. et al, Acta Physiol. Scand. 1994, 152, 349-350). Male Lister Hooded rats were used in these experiments and were divided into three groups (Group 1 : vehicle; Group 2: chlomethiazole (CMZ); Group 3: a compound of formula I). The sample size in each was 11 to 15. The animal was anaesthetised and the carotid artery exposed. A heat rounded dermalon suture (3/0) of a specified diameter was introduced into the ligated carotid artery, past the bifurcations of the external and common carotid, the internal carotid and the pterygopalatine artery, into the intracranial circulation. The filament then lodged in the narrow proximal anterior carotid occluding the middle cerebral artery. After 90 min. of middle cerebral artery occlusion, the filament was removed, allowing re-circulation.
22.5 h following reperfusion, the animal was perfused via the transaortic route, using 200 ml of a 4 percent solution of tetrazolium chloride warmed to 37° C. Following perfusion, the brain was removed and immersion fixed in 10 percent formalin/saline for at least 48 h. Following fixation, the brain was sliced into 0.5 mm sections on a vibroslice. Using this technique, viable tissue was stained dark red and infarcted tissue remains unstained. The area of infarction on each section was measured, and the total volume of infarction in the hemisphere, cortex and striatum computed, using the Kontron image analysis system.
The experimental data are displayed in Figure 1 which shows the effect of (i) vehicle; (ii) 128 mg/kg of clomethiazole dosed intraperitoneally (i.p.); and (iii) 30 mg/kg i.p. of compound (lb), on infarct volumes (assessed using tetrazolium histochemistry) after transient middle cerebral artery occlusion. Data are displayed as (mean + SEM) using absolute infarct volumes in mm3. In Figure 1, ** signifies p < 0.01, and * signifies p < 0.05 in the t test.
Figure 1 illustrates that compound (lb) exhibits significant neuroprotection at a dose of 30 mg/kg i.p. in the rat transient MCAo model. Clomethiazole at a dose of 128 mg/kg i.p. was found not to be effective in this model (see Sydserff, S.G. et al.,. Br. J. Pharmacol. 1995, 114, 1631-1635).
Mouse permanent middle cerebral artery occlusion ischaemia model
Adult male C57B1 mice (20-25 g, n = 10 per group) were administered a compound of formula (I) (10 mg/kg) or vehicle (60% PEG400 in water) i.p. 30 minutes prior to middle cerebral artery (MCA) occlusion. Under halothane anaesthesia (1.5% halothane in nitrous oxide: oxygen (70:30)), a small craniectomy was made to expose the left MCA. The distal portion of the MCA was occluded by electrocoagulation. The incision site was sutured and anaesthetics withdrawn. 24 h following MCA occlusion, the mouse was euthanised, the brain removed and immersed in 4% tetrazolium chloride to visualise the area of infarction (Backhaus C. et al, J. Pharm Methods 1992, 27, 27-32). Brains were then stored in 10% formalin saline. The area of infarction as visible on the cortical surface was then computed using a PC digital imaging system (KS300, Imaging Associates, UK). Data generated is absolute area of infraction in mm for each animal. Mean infarct areas were compared by unpaired t-tests with significance taken at p < 0.05.
The experimental results are displayed in Figure 2 which shows the effect of (i) vehicle; and (ii) 60 mg/kg i.p. of compound (lb) on infarction after permanent middle cerebral artery occlusion.
Figure 2 shows that that compound (lb) exhibits significant neuroprotection at a dose of 60 mg/kg i.p. in the mouse permanent MCAo model.
Further experiments have shown that the following compounds produce significant neuroprotection at a dose of <100mg/kg in the mouse permanent middle cerebral artery occlusion ischaemia model: (R)-3-(4-Fluorophenyl)-N-(2-hydroxypropyl)azetidine-l -carboxamide (20); (3-(4-Chlorophenyl)-7V-(2-propynyl)azetidine- 1 -carboxamide (21); (S)-3-(4-Fluorophenyl)-N-(2-hydroxypropyl)azetidine- 1 -carboxamide (23); and (S)-3-(4-(Trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine carboxamide (34).
Claims
1. Use of a compound of formula (I)
(I) wherein R1 is aryl; and R2 is hydrogen or alkyl; or a pharmaceutically acceptable salt or prodrug thereof in the manufacture of a medicament for neuroprotection in a subject or for the treatment of cerebral ischaemia, central nervous system injury or eye diseases.
2. A use according to claim 1 wherein R1 is an aryl group selected from phenyl and naphthyl.
3. A use acording to claim 1 or 2 wherein R1 has 1, 2 or 3 substituent groups.
4. A use according to any preceding claim wherein R1 is substituted with one or more substituent groups selected from halo, trifluoromethyl and tertiary-butyl.
5. A use according to claim 4 wherein said halo groups are selected from chloro and fluoro.
6. A use according to claim 1, 2, 3, 4 or 5 wherein R1 is a meta- or para-substituted phenyl group.
7. A use according to claim 1 wherein R1 is selected from 4-chlorophenyl, 4-fluorophenyl, 4-(trifluoromethyl)phenyl and 3-(trifluoromethyl)phenyl.
8. A use according to claim 1, 2, 3, 4 or 5 wherein R1 is selected from a 2,3-disubstituted phenyl group, a 2,4-disubstituted phenyl group, a 3,4-disubstituted phenyl group and a 3,5- disubstituted phenyl group.
9. A use according to claim 8 wherein R1 is substituted by two halo groups, the same or different, or by one halo group and one trifluoromethyl group.
10. A use according to claim 9 wherein R1 is dichloro-substituted, difluoro-substituted, chloro-fluoro-substituted or fiuoro-trifluoromethyl-substituted.
11. A use according to claim 1 wherein R1 is selected from 3,4-dichlorophenyl, 3,4- difluorophenyl, 3-chloro-4-fluorophenyl, 4-chloro-3 -fluorophenyl, 3-fluoro-4- (trifluoromethyl)phenyl, 4-fluoro-3-(trifluoromethyl)phenyl and 3 -chloro-5 -fluorophenyl.
12. A use according to any one of claims 1 to 11 wherein R2 is alkyl.
13. A use according to any one of claims 1 to 12 wherein R2 is Cι-8 alkyl.
14. A use according to any one of claims 1 to 13 wherein R2 is alkenyl, alkynyl, hydroxyalkyl or alkoxyalkyl.
15. A use according to any one of claims 1 to 13 wherein R2 is unsubstituted saturated cyclic or acyclic hydrocarbyl.
16. A use according to any one of claims 1 to 13 wherein R2 is propyl, 2-propenyl, 2- propynyl or 2-hydroxypropyl.
17. A use according to claim 1 wherein the compound of formula (I) is selected from: (R)-3-(4-Fluorophenyl)-N-(2-hydroxypropyl)azetidine- 1 -carboxamide; (3-(4-Chlorophenyl)-N-(2-propynyl)azetidine- 1 -carboxamide;
(S)-3-(4-Fluorophenyl)-7V-(2-hydroxypropyl)azetidine- 1 -carboxamide; and (S)-3-(4-(Trifluoromethyl)phenyl)-7V-(2-hydroxypropyl)azetidine carboxamide, or a pharmaceutically acceptable salt or prodrug thereof.
18. A use according to claim 1 wherein the compound of formula (I) is 3-(4- (trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine- 1 -carboxamide or a pharmaceutically acceptable salt or prodrug thereof.
19. A use according to claim 1 wherein the compound of formula (I) is the (R) enantiomer of 3 -(4-(trifluoromethyl)phenyl)-N-(2-hydroxypropyl)azetidine- 1 -carboxamide (lb)
(lb)
or a pharmaceutically acceptable salt or prodrug thereof, substantially free of its (S)- enantiomer.
20. A use according to any preceding claim wherein said medicament comprises a pharmaceutically acceptable carrier and as active ingredient an effective amount of compound (I).
21. A use according to claim 20 wherein said carrier comprises a cyclodextrin or an ether derivative thereof.
22. A use according to any preceding claim wherein the medicament further comprises a buffer system, an isotonizing agent and water.
23. Use according to any of preceding claim wherein the compound of formula (I) is in combination with one or more additional drugs useful in neuroprotection or in the treatment of cerebral ischaemia, central nervous system injury or eye diseases, the components being in the same formulation or in separate formulations for administration simultaneously or sequentially.
24. A method of neuroprotection comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) as set out in any of claims 1 to 19, or a pharmaceutically acceptable salt or prodrug thereof.
25. A method of treatment of cerebral ischaemia, central nervous system injury or eye diseases comprising administration to a subject in need of such treatment an effective dose of a compound of formula (I) as set out in any of claims 1 to 19, or a pharmaceutically acceptable salt or prodrug thereof.
26. A method according to claim 24 or 25 wherein the compound of formula (I) is administered in the form as set out in any of claims 20, 21 or 22.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9917384 | 1999-07-23 | ||
GBGB9917384.1A GB9917384D0 (en) | 1999-07-23 | 1999-07-23 | Chemical compounds-III |
PCT/GB2000/002817 WO2001007022A2 (en) | 1999-07-23 | 2000-07-21 | Azetidine compounds in cns and eye diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1196165A2 true EP1196165A2 (en) | 2002-04-17 |
Family
ID=10857862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00946187A Withdrawn EP1196165A2 (en) | 1999-07-23 | 2000-07-21 | Azetidine compounds in cns and eye diseases |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1196165A2 (en) |
JP (1) | JP2003505413A (en) |
AU (1) | AU6006000A (en) |
GB (1) | GB9917384D0 (en) |
WO (1) | WO2001007022A2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102224135A (en) * | 2008-11-24 | 2011-10-19 | Nsab神经研究瑞典公司分公司 | Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB872447A (en) * | 1958-12-23 | 1961-07-12 | Lepetit Spa | 1-carbamyl-3-substituted azetidines |
AU2178099A (en) * | 1998-01-23 | 1999-08-09 | Vernalis Research Limited | Azetidinecarboxamide derivatives for treating cns disorders |
-
1999
- 1999-07-23 GB GBGB9917384.1A patent/GB9917384D0/en not_active Ceased
-
2000
- 2000-07-21 EP EP00946187A patent/EP1196165A2/en not_active Withdrawn
- 2000-07-21 JP JP2001511908A patent/JP2003505413A/en not_active Withdrawn
- 2000-07-21 AU AU60060/00A patent/AU6006000A/en not_active Abandoned
- 2000-07-21 WO PCT/GB2000/002817 patent/WO2001007022A2/en not_active Application Discontinuation
Non-Patent Citations (1)
Title |
---|
See references of WO0107022A2 * |
Also Published As
Publication number | Publication date |
---|---|
JP2003505413A (en) | 2003-02-12 |
GB9917384D0 (en) | 1999-09-22 |
WO2001007022A3 (en) | 2001-06-14 |
WO2001007022A2 (en) | 2001-02-01 |
AU6006000A (en) | 2001-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1617839B1 (en) | The use of azetidinecarboxamide derivatives in therapy | |
US20040209861A1 (en) | Combination of a CB1 receptor antagonist and of a product which activatives dopaminergic neurotransmission in the brain, the pharmaceutical compositions comprising them and their use in the treatment of parkinson's disease | |
CN101355938A (en) | Pharmaceutical use of substituted amides | |
JP2006522747A (en) | Pharmaceutical use of condensed 1,2,4-triazole | |
JP2008506738A (en) | INDORON DERIVATIVE, PROCESS FOR PRODUCING THE SAME AND USE THEREOF | |
EP1568688B1 (en) | Therapeutic agent for respiratory disease containing 4-hydroxypiperidine derivative as active ingredient | |
AU2019253831B2 (en) | Compositions and methods for treating neurodegenerative diseases | |
TW200803839A (en) | Use of a CB1 antagonist for treating side effects and negative symptoms of schizophrenia | |
TW200904408A (en) | Hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide | |
WO2001007023A2 (en) | Azetidine compounds in cns and eye diseases | |
ES2260910T3 (en) | METHODS AND COMPOSITIONS THAT USE TERFENADINE METABOLITES IN COMBINATION WITH LEUCOTRIEN INHIBITORS. | |
EP1196165A2 (en) | Azetidine compounds in cns and eye diseases | |
WO2001007043A1 (en) | Azetidine carboxamide derivatives for the treatment of cns disorders | |
US6403574B1 (en) | Azetidinecarboxamide derivatives for treating CNS disorders | |
US6514961B1 (en) | Azetidinecarboxamide derivatives for the treatment of CNS disorders | |
US6831078B1 (en) | Azetidinecarboxamide derivatives for treating CNS disorders | |
CA3151863C (en) | Compound as potassium channel regulator and preparation and use thereof | |
WO2024040155A1 (en) | Isoxazolidines as ripk1 inhibitors and use thereof | |
JP2003246732A (en) | Neurotmesis remedy comprising 1,2-ethanediol derivative or salt thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20020109 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: AL;LT;LV;MK;RO;SI |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20040203 |